Market news

Cullinan Therapeutics' stock pullback may be a strong entry ahead of December 2026 autoimmune updates. Read more on CGEM here.

Cullinan Therapeutics (NASDAQ:CGEM) outlined upcoming clinical milestones across its immunology and oncology pipeline, including a planned December update for its CD19-directed T-cell engager CLN-978 and data presentations for other programs in November and the fourth quarter. President and CEO Nad

Cullinan Therapeutics (NasdaqGS:CGEM) plans to report clinical data updates from three T cell engager programs in Q4 2026. The update will include new results for autoimmune and oncology candidates Velinotamig, CLN-978, and CLN-049. Cullinan also anticipates starting a Phase 2 study of CLN-049 after discussions with the US Food and Drug Administration. The planned Q4 2026 readouts and CLN-049 Phase 2 launch sit alongside a broader picture our research has uncovered. Take a look at 3 warning...

Cullinan Therapeutics stock moves after Phase 3 zipalertinib data Cullinan Therapeutics (CGEM) is back in focus after Phase 3 REZILIENT3 trial results showed zipalertinib plus chemotherapy improved progression free survival for EGFR exon 20 insertion non small cell lung cancer patients. Recent trading tells a mixed story for Cullinan Therapeutics. The share price has fallen about 22% over the past day and over the last month, and is down close to 9% over 90 days. However, the year to date...

Biotech stocks widely slumped Wednesday, with Rapport, Climb Bio and Cullinan among some of the hardest-hit names.

CAMBRIDGE, Mass., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, Septem

Limited Spec Automotive announced the availability of a 2027 Rolls-Royce Cullinan Base at its Miami showroom, giving Florida collectors and luxury vehicle enthusiasts access to one of the most sought-after SUVs on the market.

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) disclosed detailed Phase 3 REZILIENT3 results on September 13, 2026, in patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. Zipalertinib plus chemotherapy achieved median progression-free survival of 14.5 months, compared with 8.5 months for chemotherapy alone. Progression-free survival, or […]

Detailed price information for Molina Healthcare Inc (MOH-N) from The Globe and Mail including charting and trades.

Five additional national and regional retailers announced to join DICK’S House of Sport at the ceremonial retail groundbreaking for the 1.3 million square foot super regional destinationPeoria, IL, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Cullinan Properties announced it has achieved more than 500,000 square feet of executed deals current or coming to Rock Run Collection, including naming five additional national and regional retailer tenants alongside previously announced DICK’S House of Sport. The a

Hong Kong’s biggest developer reported underlying profit of HK$22.85 billion, as the city’s property market continues to recover.

Cullinan Therapeutics offers a unique, multi-asset portfolio with near-, mid-, and long-term value drivers. Find out why CGEM stock is a buy.

The findings position their drug, zipalertinib, as a threat to multiple approved medicines — while setting a bar for others in testing.

Cullinan Therapeutics (CGEM) drew investor attention after receiving positive U.S. Food and Drug Administration feedback on its End of Phase 1 meeting for CLN-049 in acute myeloid leukemia. See our latest analysis for Cullinan Therapeutics. Against this backdrop, Cullinan Therapeutics’ share price has eased in the very short term, with a 1-day share price return of 1.49% lower and a 7-day return of 2.49% lower. However, the 90-day share price return of 31.88% and year to date share price...

CAMBRIDGE, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced positive feedback from the U.S. Food and Drug Administration (FDA) following an End-of-Phase 1 (EOP1) meeting for CLN-049, a FLT3xCD3 T cell engager being evaluated in patients with acute myeloid leukemia (AML). The